Several new drugs have been approved for metastatic prostate cancer (PCa) since 2004, but declines in PCa screening due to a 2012 US Preventive Screening Task Force (USPSTF) recommendation against it may have eroded drug-related survival gains, according to investigators of a new study presented during the American Urological Association 2020 Virtual Experience.
Michael Adam Feuerstein, MD, of Northwell Health in New York City, and colleagues analyzed data from 34,888 men (median age 72 years) with metastatic PCa from 18 Surveillance, Epidemiology, and End Results (SEER) registries to better understand disease trends. From 2004 to 2015, there was an uptick in de novo M1 diagnoses from 10.2 to 12.1 per 100,000. The incidence of PCa with bone metastasis with or without lymph node involvement (M1b) increased, whereas incidence of disease in non-regional lymph nodes (M1a) and distant metastatic disease (M1c) remained stable.
Overall survival at 2 years for M1 disease increased only slightly from 50% in 2004 to 54% in 2014; during that same period, cancer-specific survival at 2 years rose from 60% to 63%.
“The survival trend may be less pronounced than expected due to decreased screening and later diffusion of effective treatments,” according to Dr Feuerstein’s team.
Rasul R, Golden A, Feuerstein M, et al. Trends in incidence and survival among men with metastatic prostate cancer: SEER analysis 2004-2015. Presented at the American Urological Association 2020 Virtual Experience, May 15-19, 2020. Abstract MP64-05.
This article originally appeared on Renal and Urology News